Trial Profile
An open-label study evaluating the safety and effectiveness of OROS methylphenidate hydrochloride (Concerta) in adults with attention deficit hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2011
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Inc
- 14 May 2007 Status changed from in progress to completed.
- 18 Dec 2005 New trial record.